Agentix Corp
agentixcorp.comWhat Do They Do?
Develops drug candidates for metabolic diseases, including obesity and fatty liver disease, with plans to partner with larger biopharma companies for later-stage commercialization.
10-K for FY2026, filed Jul 1, 2026As a result of the Share Exchange Agreement, we plan to focus our business efforts on the development and commercialization of novel…View ↗
The above factors will in part drive the global demand for biopharmaceuticals, along with an increase in the global acceptance of…View ↗
AGTX-2004 (also known as DBPR211) is a peripherally-acting CB1 receptor antagonist that has demonstrated efficacy in animal models of…View ↗
AGTX-2003View ↗
Who Are Their Customers?
The company plans to develop drug candidates through initial clinical efficacy, then partner with larger biopharma companies for the pivotal stages of commercialization.
10-K for FY2026, filed Jul 1, 2026The above factors will in part drive the global demand for biopharmaceuticals, along with an increase in the global acceptance of…View ↗
How Are They Changing?
- Net income
-
Sources
10-Q for Q1 FY2027, filed Aug 10, 2026
−$117.7KView ↗
- ▼ −37% (Loss)
- vs −$185.8K in Q1 FY2026
Who Do They Compete With?
Competes with Novo Nordisk, Johnson & Johnson, Pfizer, Hoffmann-La Roche, Eli Lilly and, Biogen, Merck &, Sanofi, Bristol Myers Squibb, and Bayer
10-K for FY2026, filed Jul 1, 2026The biopharma industry is characterized by fierce competition, is growing rapidly, evolving constantly, and the possibility for innovative…View ↗
Loading...
